Prenetics Global (PRE) Insider Cheng Yin Pan Sells 15,873 Shares

Insider Buying and Selling at Prenetics Global Limited

Internal trading documents filed with regulators show a flurry of activity at Prenetics Global Limited on June 15, 2026. Insider Cheng Yin Pan engaged in transactions involving 15,873 shares of the company on that date, which included both acquisitions and dispositions. In addition, fellow insider David Vanderveen participated in trading by selling 8,681 shares and acquiring 6,944 shares on the exact same day. These internal moves follow earlier coverage from June 15 and June 16, 2026, when Benchmark reaffirmed its positive stance on the consumer health firm.

Stock Price Trades Near Key Moving Averages

Shares of Prenetics Global Limited on the NasdaqGM under the ticker PRE sit at a spot price of $20.51, resting between a 52-week low of $11.37 and a 52-week high of $27.24. The equity trades close to its 50-day moving average of $21.34 while staying safely above its 200-day moving average of $18.92. With a beta of 0.309, the shares exhibit lower volatility than the broader market. The prior close for the equity was recorded at $24.19.

Wall Street Analyst Views and Price Targets

Financial institutions maintain a strong interest in the company's trajectory, backed by a consensus recommendation of strong_buy across seven analyst opinions. On October 12, 2026, Lucid Capital Markets initiated coverage with a buy rating and a $54.00 price target. Earlier, Craig-Hallum started coverage on September 17, 2026, setting a buy rating and a $40.00 target. B. Riley Securities also issued a buy rating and a $37.00 price target on August 27, 2026. Furthermore, Benchmark maintained a buy rating on July 15, 2026, adjusting its price target to $40.00 from $30.00. The overall mean price target rests at $35.86, with high estimates reaching $40.00 and low estimates at $30.00.

Consumer Health Focus in Hong Kong

Based in Quarry Bay, Hong Kong, Prenetics Global Limited operates as a consumer health sciences company focusing on science-backed longevity products under the IM8 brand. The enterprise also runs the CircleDNA genetic testing brand, utilizing sequencing technology to provide personalized reports. Founded in 2014, the firm employs 98 people within the packaged foods and health sector.

Upcoming Earnings and Reporting Schedule

Market participants look ahead to the next corporate earnings release, which is scheduled for November 10, 2026. This upcoming report will offer fresh insight into the company's financial results, revenue growth, and profitability metrics as insiders and analysts continue to monitor the equity's progress.